Walker on Progress

Harbour BioMed and Evinova are joining forces to leverage artificial intelligence in drug R&D, aiming to slash timelines and costs in the increasingly competitive biopharmaceutical landscape. A deep dive into the partnership and its implications.

A small medical device firm is making a bold move into the lucrative bone regeneration market, partnering with an Italian biomaterials innovator. Will this gamble pay off, or will established players shut them out?

MediciNova’s MN-166 (ibudilast) has received a key industry award, highlighting its potential in treating ALS. This comes amidst growing challenges in neurological disease research and limited effective treatments.

Innovative packaging protects delicate therapies, unlocking potential for personalized medicine. Cryoport’s solution is poised to capitalize on the booming regenerative medicine market.

ALZpath’s pTau217 antibody is earning accolades and gaining traction in the diagnostics market, promising earlier, more accessible detection of Alzheimer’s disease – but what are the broader implications?

RenovoRx strengthens its pancreatic cancer program with a key advisory board appointment & promising data for its localized drug delivery system, potentially revolutionizing treatment.

RenovoRx strengthens its pancreatic cancer program with a key advisory board appointment & promising data for its localized drug delivery system, potentially revolutionizing treatment.

Small biotech Lisata Therapeutics wins major award for its innovative cancer drug delivery system, offering renewed optimism for hard-to-treat cancers like pancreatic cancer. A deep dive into the technology and future prospects.

A new approach to surgical site infection prevention, leveraging localized antibiotic delivery, has earned recognition and shows strong clinical results, potentially disrupting the $X billion market.

A breakthrough in genomic mapping offers a more complete picture of cancer-causing genetic changes, potentially revolutionizing diagnosis and treatment for leukemia patients.

The annual BioTech Breakthrough Awards highlight a surge in AI-driven innovation across the life sciences. We dissect the winners, trends, and investment signals shaping the future of biotech.

NewcelX Ltd. has appointed leading neuroimmunologist Prof. Tamir Ben-Hur to its Scientific Advisory Board, bolstering the biotech’s efforts to develop groundbreaking cell & small-molecule therapies for debilitating diseases like ALS and Type 1 Diabetes.

Dutch biotech firm SkylineDx is transforming cancer diagnosis with its innovative genomic tests, validated by research and earning industry recognition. Learn how they’re tailoring treatments for better patient outcomes.

New software from Golden Helix aims to democratize genomic data analysis, offering flexible pricing, cloud deployment & enhanced interpretation tools for labs of all sizes.

Amidst rising regulatory pressure and consumer demand for ethical sourcing, Oritain is expanding its scientific network. But are the promised acquisitions and new membership model fully materialized?

Arcoris Bio’s MUSE® platform is poised to disrupt digital pathology, offering unprecedented sensitivity and multiplexing for faster, more accurate diagnostics. A new $7.1M seed round will fuel industrialization and partnerships.

A new partnership aims to accelerate drug development by integrating antibody discovery with manufacturing. The collaboration highlights a growing trend towards specialized antibodies and the impact of private equity in biomanufacturing.

Wes Carter of Atlantic Packaging is redefining corporate sustainability with a proactive ‘voluntary mitigation offset’ program, earning him recognition as a leader in environmental stewardship and sparking a debate about the future of industry responsibility.

Two seasoned biopharma consultants are betting on a new firm, MOMENTUS, to navigate the industry’s growing complexities. The launch prioritizes AI-driven solutions alongside deep subject-matter expertise.

A new $120 million investment from AstraZeneca, Eli Lilly & Merck is poised to transform Virginia into a national hub for advanced pharmaceutical manufacturing, bolstering supply chain resilience and workforce development.